Kadmon and Meiji Collaborate to Form JV for the Development and Commercialization of KD025 in Japan

 Kadmon and Meiji Collaborate to Form JV for the Development and Commercialization of KD025 in Japan

Kadmon and Meiji Collaborate to Form JV for the Development and Commercialization of KD025 in Japan

Shots:

  • Kadmon to receive ~$29M as development, regulatory & commercial milestones with royalties on sales of KD025 in Japan and certain other Asian countries
  • The JV, named as Romeck Pharma has the HQ in Japan with shared oversight between Kadmon and Meiji
  • KD025 is ROCK2 inhibitor with the potential to treat inflammatory and fibrotic diseases, being studies in a clinical study for cGVHD in the US & has received FDA’s BT designation for cGVHD following 2L+ systemic therapies

Click here to­ read full press release/ article | Ref: Kadmon | Image: Kadmon

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post